Multisystem Inflammatory Syndrome in Adults After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Coronavirus Disease 2019 (COVID-19) Vaccination. (28th November 2021)

• Record Type: Journal Article
• Authors: Belay, Ermias D; Godfred Cato, Shana; Rao, Agam K; Abrams, Joseph; Wyatt Wilson, W; Lim, Sarah; Newton-Cheh, Christopher; Melgar, Michael; DeCuir, Jennifer; Webb, Brandon; Marquez, Paige; Su, John R; Meng, Lu; Grome, Heather N; Schlaudecker, Elizabeth; Talaat, Kawsar; Edwards, Kathryn; Barnett, Elizabeth; Campbell, Angela P; Broder, Karen R; Bamrah Morris, Sapna
• Is Part Of: Clinical infectious diseases. Volume 75:Number 1(2022)
• Page Start: e741
• Page End: e748
• Publication Date: 2021-11-28
• Subjects: coronavirus -- COVID-19 -- MIS-A -- MIS-C -- multisystem inflammatory syndrome in adults; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciab936
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Multisystem inflammatory syndrome in adults (MIS-A) was reported in association with the coronavirus disease 2019 (COVID-19) pandemic. MIS-A was included in the list of adverse events to be monitored as part of the emergency use authorizations issued for COVID-19 vaccines. Methods: Reports of MIS-A patients received by the Centers for Disease Control and Prevention (CDC) after COVID-19 vaccines became available were assessed. Data collected on the patients included clinical and demographic characteristics and their vaccine status. The Vaccine Adverse Events Reporting System (VAERS) was also reviewed for possible cases of MIS-A. Results: From 14 December 2020 to 30 April 2021, 20 patients who met the case definition for MIS-A were reported to CDC. Their median age was 35 years (range, 21–66 years), and 13 (65%) were male. Overall, 16 (80%) patients had a preceding COVID-19-like illness a median of 26 days (range 11–78 days) before MIS-A onset. All 20 patients had laboratory evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Seven MIS-A patients (35%) received COVID-19 vaccine a median of 10 days (range, 6–45 days) before MIS-A onset; 3 patients received a second dose of COVID-19 vaccine 4, 17, and 22 days before MIS-A onset. Patients with MIS-A predominantly had gastrointestinal and cardiac manifestations and hypotension or shock. Conclusions: Although 7 patients were reported to have received COVID-19 vaccine, all had evidence of prior SARS-CoV-2 infection. Given the widespread use of COVID-19 vaccines, the lack of reporting of MIS-A associated with vaccination alone, without evidence of underlying SARS-CoV-2 infection, is reassuring. Abstract : Seven of 20 MIS-A patients received COVID-19 vaccination before illness onset. All patients had evidence of prior SARS-CoV-2 infection. Given widespread COVID-19 vaccinations in the United States, the lack of reporting of MIS-A associated with vaccination alone is reassuring.